drugset / Trial / NCT03925974
KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, phase 2 study of KN026 in subjects with HER2 expressing gastric/gastroesophageal junction cancer to evaluate efficacy and safety. The subjects will receive KN026 10 mg/kg QW or 20 mg/kg Q2W or 30mg/kg Q3W until progressive disease, unacceptable toxicity or death.
Timeline
- Start
- 2019-06-17
- Primary completion
- 2022-05-31
- Completion
- 2022-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KN026 | Monoclonal antibody | 10 mg/kg | — |
| Subject | KN026 | Monoclonal antibody | 20 mg/kg | — |
| Subject | KN026 | Monoclonal antibody | 30 mg/kg | — |